ERBB2 and breast cancer: Bartkova et al. examined the expression of γH2AX in breast cancer and reported a higher proportion of positivity (> 1%) in TNBC (67%, 86/129) than in tumors with positive hormone receptors or HER2 overexpression, (44%, 343/773) [13].